SCHEMBL5831014

SCHEMBL5831014

O=S(=O)(Nc1nnc(-c2ccccc2Cl)s1)c1ccc(-c2ccccc2)cc1

nearest known ligand 0.68

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MEN1 O00255 3/20 0.68
KMT2A Q03164 3/20 0.68
LMNA P02545 1/20 0.68
ALOX12 P18054 1/20 0.68
HTT P42858 1/20 0.68
KDM1A O60341 3/20 0.50
CA1 P00915 3/20 0.49
CA2 P00918 3/20 0.49
CA5A P35218 3/20 0.49
CA5B Q9Y2D0 3/20 0.49
CA12 O43570 2/20 0.49
CA3 P07451 2/20 0.49
CA6 P23280 2/20 0.49
CA7 P43166 2/20 0.49
CA9 Q16790 2/20 0.49
PTGS2 P35354 1/20 0.48
PKM P14618 2/20 0.48
KDM4E B2RXH2 1/20 0.48
NPC1 O15118 1/20 0.48
ALDH1A1 P00352 1/20 0.48

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5830937 0.85 MEN1 (0.81) MEN1KMT2ALMNAALOX12HTT
SCHEMBL5831323 0.83 MEN1 (0.57) MEN1KMT2ALMNAALOX12HTT
SCHEMBL5831948 0.82 MEN1 (0.55) MEN1KMT2ALMNAALOX12HTT
SCHEMBL5830368 0.78 CA1 (0.50) MEN1KMT2ALMNAALOX12HTT
SCHEMBL2762642 0.78 KDM1A (0.74) MEN1KMT2AKDM1A
SCHEMBL5831119 0.78 KDM1A (0.54) MEN1KMT2ALMNAALOX12HTT
SCHEMBL23631834 0.78 MEN1 (0.58) MEN1KMT2ALMNAALOX12HTT
SCHEMBL31180050 0.78 MEN1 (0.58) MEN1KMT2ALMNAALOX12HTT
SCHEMBL5831168 0.77 PTGES2 (0.50) MEN1KMT2ALMNAALOX12HTT
SCHEMBL5831646 0.77 GUSB (0.49) MEN1KMT2ALMNAALOX12HTT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1461327-A1 INHIBITORS OF 11-BETA-HYDROXY STEROID DEHYDROGENASE TYPE 1 BIOVITRUM AB (SE) 2004-09-29 EP claimed
US-20030130258-A1 Antidiabetic agents; liver disorders; cardiovascular disorders; dietetics BIOVITRUM AB (SE) 2003-07-10 US claimed
WO-2003044000-A1 INHIBITORS OF 11-BETA-HYDROXY STEROID DEHYDROGENASE TYPE 1 BIOVITRUM AB (SE) 2003-05-30 WO claimed
US-7074788-B2 Inhibitors of 11-beta-hydroxy steroid dehydrogenase type 1 BIOVITRUM AB (SE) 2006-07-11 US disclosed
WO-2004113310-A1 USE OF AN INHIBITOR OF 11-B-HYDROXYSTEROID DEHYDROGENASE TYPE 1 COMPOUNDS FOR PROMOTING WOUND HEALING BIOVITRUM AB (SE) 2004-12-29 WO disclosed
US-20030130258-A1 Antidiabetic agents; liver disorders; cardiovascular disorders; dietetics BIOVITRUM AB (SE) 2003-07-10 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20030130258-A1 Antidiabetic agents; liver disorders; cardiovascular disorders; dietetics CPT1A, HSD11B1, CES1 MEN1 903/4885KMT2A 2980/4885LMNA 1897/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.